Consistent with this notion, pharmacological AMPK-induced inhibition of DNL has been suggested to play a significant role in the improvement of hepatic steatosis of animal models where DNL mainly contributes to hepatic TG accumulation [7,8]. The gene discussed is PRKAA2; the disease is fatty liver disease.